Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the… Read more
Ildong Holdings Co Ltd (000230) - Net Assets
Latest net assets as of September 2025: ₩308.95 Billion KRW
Based on the latest financial reports, Ildong Holdings Co Ltd (000230) has net assets worth ₩308.95 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩813.62 Billion) and total liabilities (₩504.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩308.95 Billion |
| % of Total Assets | 37.97% |
| Annual Growth Rate | 6.25% |
| 5-Year Change | -16.89% |
| 10-Year Change | -27.43% |
| Growth Volatility | 30.07 |
Ildong Holdings Co Ltd - Net Assets Trend (1999–2024)
This chart illustrates how Ildong Holdings Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ildong Holdings Co Ltd (1999–2024)
The table below shows the annual net assets of Ildong Holdings Co Ltd from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩254.00 Billion | +49.50% |
| 2023-12-31 | ₩169.90 Billion | +0.47% |
| 2022-12-31 | ₩169.10 Billion | -7.77% |
| 2021-12-31 | ₩183.34 Billion | -40.01% |
| 2020-12-31 | ₩305.61 Billion | -4.82% |
| 2019-12-31 | ₩321.09 Billion | +94.67% |
| 2018-12-31 | ₩164.95 Billion | -5.55% |
| 2017-12-31 | ₩174.64 Billion | +63.46% |
| 2016-12-31 | ₩106.84 Billion | -69.47% |
| 2015-12-31 | ₩349.98 Billion | +5.12% |
| 2014-12-31 | ₩332.95 Billion | +1.94% |
| 2013-12-31 | ₩326.60 Billion | +0.67% |
| 2012-12-31 | ₩324.42 Billion | +4.59% |
| 2011-12-31 | ₩310.17 Billion | +5.14% |
| 2010-12-31 | ₩295.00 Billion | +5.26% |
| 2009-12-31 | ₩280.27 Billion | +35.49% |
| 2008-12-31 | ₩206.86 Billion | +5.67% |
| 2007-12-31 | ₩195.76 Billion | +13.16% |
| 2006-12-31 | ₩172.99 Billion | +17.86% |
| 2005-12-31 | ₩146.78 Billion | +17.46% |
| 2004-12-31 | ₩124.97 Billion | +18.22% |
| 2003-12-31 | ₩105.71 Billion | +11.46% |
| 2002-12-31 | ₩94.84 Billion | +19.49% |
| 2001-12-31 | ₩79.37 Billion | +18.50% |
| 2000-12-31 | ₩66.98 Billion | +20.01% |
| 1999-12-31 | ₩55.81 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ildong Holdings Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17694027818000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩310.83 Billion | 232.16% |
| Total Equity | ₩133.89 Billion | 100.00% |
Ildong Holdings Co Ltd Competitors by Market Cap
The table below lists competitors of Ildong Holdings Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nitratos de Chile SA
SN:NITRATOS
|
$49.57 Million |
|
BABYTREE GROUP
F:BTR
|
$49.60 Million |
|
Daaz Bara Lestari Tbk
JK:DAAZ
|
$49.60 Million |
|
Mobiletron Electronics Co Ltd
TW:1533
|
$49.61 Million |
|
LIWANLI Innovation Co Ltd
TW:3054
|
$49.55 Million |
|
Votum SA
WAR:VOT
|
$49.55 Million |
|
Nebag ag
SW:NBEN
|
$49.55 Million |
|
Pruksa Holding Public Company Limited
BK:PSH
|
$49.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ildong Holdings Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,962,138,820 to 133,886,190,470, a change of 94,924,051,650 (243.6%).
- Net income of 63,038,086,160 contributed positively to equity growth.
- Dividend payments of 1,206,009,000 reduced retained earnings.
- Share repurchases of 386,338,160 reduced equity.
- Other factors increased equity by 33,478,312,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩63.04 Billion | +47.08% |
| Dividends Paid | ₩1.21 Billion | -0.9% |
| Share Repurchases | ₩386.34 Million | -0.29% |
| Other Changes | ₩33.48 Billion | +25.01% |
| Total Change | ₩- | 243.63% |
Book Value vs Market Value Analysis
This analysis compares Ildong Holdings Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.70x to 0.91x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩15335.50 | ₩10770.00 | x |
| 2018-12-31 | ₩15220.59 | ₩10770.00 | x |
| 2019-12-31 | ₩12183.33 | ₩10770.00 | x |
| 2020-12-31 | ₩10866.82 | ₩10770.00 | x |
| 2021-12-31 | ₩4722.60 | ₩10770.00 | x |
| 2022-12-31 | ₩1046.13 | ₩10770.00 | x |
| 2023-12-31 | ₩3450.39 | ₩10770.00 | x |
| 2024-12-31 | ₩11856.64 | ₩10770.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ildong Holdings Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 47.08%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.59%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 6.38x
- Recent ROE (47.08%) is above the historical average (-27.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 8.25% | 3.91% | 0.62x | 3.39x | ₩-976.37 Million |
| 2000 | 11.58% | 4.88% | 0.79x | 2.98x | ₩993.77 Million |
| 2001 | 13.48% | 5.33% | 1.01x | 2.50x | ₩2.55 Billion |
| 2002 | 15.51% | 6.49% | 1.08x | 2.21x | ₩4.89 Billion |
| 2003 | 14.23% | 5.89% | 1.09x | 2.21x | ₩4.18 Billion |
| 2004 | 8.43% | 3.51% | 1.21x | 1.99x | ₩-1.84 Billion |
| 2005 | 15.04% | 6.56% | 1.20x | 1.91x | ₩6.81 Billion |
| 2006 | 14.88% | 6.71% | 1.21x | 1.83x | ₩7.58 Billion |
| 2007 | 12.87% | 6.26% | 1.08x | 1.91x | ₩5.04 Billion |
| 2008 | 9.56% | 4.81% | 0.93x | 2.13x | ₩-839.03 Million |
| 2009 | 12.60% | 8.30% | 0.80x | 1.90x | ₩6.77 Billion |
| 2010 | 6.76% | 5.35% | 0.65x | 1.93x | ₩-8.89 Billion |
| 2011 | 8.81% | 7.83% | 0.68x | 1.65x | ₩-3.68 Billion |
| 2012 | 5.22% | 4.66% | 0.67x | 1.67x | ₩-15.49 Billion |
| 2013 | 1.99% | 1.64% | 0.63x | 1.93x | ₩-26.09 Billion |
| 2014 | 3.58% | 2.84% | 0.67x | 1.87x | ₩-21.30 Billion |
| 2015 | 6.03% | 54.78% | 0.05x | 2.03x | ₩-13.83 Billion |
| 2016 | 253.86% | 652.39% | 0.20x | 1.95x | ₩255.51 Billion |
| 2017 | 0.38% | 1.59% | 0.15x | 1.59x | ₩-16.67 Billion |
| 2018 | -2.27% | -7.91% | 0.18x | 1.62x | ₩-20.09 Billion |
| 2019 | -16.32% | -7.69% | 0.36x | 5.85x | ₩-36.22 Billion |
| 2020 | -15.63% | -3.22% | 0.75x | 6.51x | ₩-31.46 Billion |
| 2021 | -132.93% | -11.97% | 0.64x | 17.27x | ₩-76.22 Billion |
| 2022 | -866.44% | -15.15% | 0.78x | 73.02x | ₩-103.53 Billion |
| 2023 | -152.94% | -9.33% | 0.73x | 22.51x | ₩-63.48 Billion |
| 2024 | 47.08% | 9.59% | 0.77x | 6.38x | ₩49.65 Billion |
Industry Comparison
This section compares Ildong Holdings Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $198,739,678,933
- Average return on equity (ROE) among peers: 0.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ildong Holdings Co Ltd (000230) | ₩308.95 Billion | 8.25% | 1.63x | $49.55 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |